Money Concepts Capital Corp Has $8.36 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Money Concepts Capital Corp lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 90,538 shares of the biopharmaceutical company's stock after selling 3,776 shares during the quarter. Money Concepts Capital Corp's holdings in Gilead Sciences were worth $8,363,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Gilead Sciences by 8.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 434,165 shares of the biopharmaceutical company's stock valued at $40,689,000 after acquiring an additional 34,549 shares during the period. Y.D. More Investments Ltd lifted its stake in Gilead Sciences by 43.3% in the 4th quarter. Y.D. More Investments Ltd now owns 1,602 shares of the biopharmaceutical company's stock valued at $148,000 after purchasing an additional 484 shares during the last quarter. Hager Investment Management Services LLC bought a new position in Gilead Sciences during the fourth quarter worth about $145,000. Stratos Investment Management LLC increased its position in Gilead Sciences by 6.2% during the fourth quarter. Stratos Investment Management LLC now owns 2,895 shares of the biopharmaceutical company's stock worth $267,000 after buying an additional 170 shares during the last quarter. Finally, Retirement Systems of Alabama raised its stake in Gilead Sciences by 31.0% in the fourth quarter. Retirement Systems of Alabama now owns 998,307 shares of the biopharmaceutical company's stock valued at $92,214,000 after buying an additional 236,453 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

NASDAQ GILD traded down $2.00 on Friday, hitting $96.04. 7,182,199 shares of the company's stock were exchanged, compared to its average volume of 6,866,207. The stock has a 50-day moving average of $93.04 and a 200-day moving average of $86.65. The stock has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. Analysts expect that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 in the last quarter. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GILD. Daiwa America raised Gilead Sciences to a "hold" rating in a report on Monday, November 18th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Mizuho raised their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. Morgan Stanley upgraded shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Finally, Oppenheimer raised their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.